Events
PAREA Events:
All Upcoming Events
IDPAT Conference
This fall, PAREA will participate in the IMBAS Psychedelic Research Conference, co-hosted by IDPAT and the Trinity College Dublin Psychedelic Research Group.
IDPAT is a non-profit organisation dedicated to increasing awareness of psychedelic research among clinicians and policymakers in Ireland. It brings together doctors, researchers, psychotherapists, and healthcare professionals working across a broad range of specialties, from general practice to psychiatry, neurology to oncology. They believe that many patients in Ireland would benefit from access to psychedelic-assisted therapy and advocate for it to become a publicly available and reimbursed treatment. They also advocate for patient access to state-funded psychedelic research trials.
We will be represented by our Project Officer, Francisca Silva, who is scheduled to speak on Friday at 2:00 PM. Her session will be followed by a 1-hour panel discussion at 4:30 PM, featuring: David Erritzoe, James Rucker, Liam Modlin, Celia Morgan, and Professor David Nutt.
We’re looking forward to meaningful dialogue, knowledge exchange, community building and to connecting with those of you who’ll be joining.
Find out more about IDPAT: https://www.idpat.ie/
From Lagging to Leading: Mental Health Innovation “Made in Europe”
Europe is at a crossroads. Mental health conditions now cause more years of ill-health than cancer, diabetes, and cardiovascular disease combined, yet psychiatric innovation has stagnated, leaving patients dependent on treatments first developed half a century ago. This neglect is not only a public health failure but also a competitiveness challenge, as Europe falls behind the US and China in life sciences investment and clinical innovation. This event will explore how Europe can move from leading to lagging in mental health innovation.
With the right policies, Europe can close the innovation gap and ensure that patients gain timely access to new treatments. A mental health “moonshot” and a coordinated EU Mental Health Strategy should mobilise funding, set ambitious goals, and provide long-term direction. Stronger incentives for high-risk and cross-sector research are needed to unlock breakthroughs where market forces alone have failed. The modernisation of regulatory frameworks must ensure that innovative combination therapies can be properly evaluated. And greater investment in infrastructure and workforce capacity is essential so that health systems are ready to deliver the next generation of treatments.
The use of novel tools such as regulatory sandboxes, to be introduced in the EU pharma reform, can enhance the responsible translation of science into care. By allowing controlled, real-world testing of innovative treatments, sandboxes can both generate crucial evidence for regulators and payers and provide safe, early access for patients. Psychedelic therapies, now in late-stage development, provide an ideal test case for how sandboxes can help bridge the gap between clinical trials and health system integration.
By taking decisive action, Europe can elevate mental health as a driver of innovation and competitiveness and turn today’s crisis into tomorrow’s success story.
NEXUS
NEXUS (Neuroscience Experts and Cross-Sector Unconventional Stakeholders) aspires to bring insights, new findings, and potential solutions to the front lines of mental health that acknowledge the connection between trauma and mental health. NEXUS strives to foster understanding, resilience, and healing for underserved communities and anyone else who has been impacted by trauma.
Through education, support, and advocacy, we aim to empower individuals and communities to thrive beyond their trauma.
UW Madison Psychedelic Symposium, Nov 13-14
The University of Wisconsin Madison Transdisciplinary Center for Research in Psychoactive Substances will hold the fifth annual Psychedelic Symposium November 13-14, 2025.
The 2025 UW-Madison Psychedelic Symposium is a dynamic and transdisciplinary event aimed at expanding awareness, fostering knowledge exchange, and bridging gaps in psychedelic research, education, and policy. The symposium will bring together researchers, graduate students, and key industry stakeholders to share knowledge and facilitate collaboration.
The term “reset” can have many different meanings, depending on the context. Traditionally, it has meant a restart, often with the goal of correcting or improving a thing or action. More broadly, reset has been used to help conceptualize technology — such as restoring a device — back to its original state, while concepts like the “The Great Reset” have described large-scale economic and societal shifts. Psychedelic science and therapy have hypothesized various kinds of resets, relating to how substances and integration might help people break out of rigid thought patterns, alleviating issues like intractable depression, anxiety, or PTSD. In the realm of wellness or psychology, reset has often referred to a mental or emotional refresh and has been associated with reevaluating behavior, changing habits, or taking a break. In 2025, reset is also a useful way to think about the psychedelic field itself.
Learn more and register here.
HoloMind: Psychedelic Therapy and Integration Conference
The Psychedelic Therapy and Integration Conference aims to scientifically and comprehensively integrate knowledge and research on the use of psychoactive substances in treating conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD), and addiction. The therapeutic application of psychoactive substances is gaining a growing following among scientists and therapists worldwide. It is already legal in the USA (Oregon), Australia, and Israel and the process of decriminalization has already started in the Netherlands. The therapeutic potential of such treatments is also being considered by the European Parliament.
HoloMind seeks to inform attendees about the latest methods for treating depression and PTSD, while also promoting harm reduction associated with the illegal use of psychoactive substances as part of our educational mission.
Learn more and register here.
Psychedelic Lived Experiences Summit, November
PAREA is proud to support the Psychedelic Lived Experiences Summit, an online gathering that bridges science and lived expertise with nuance and wisdom.
📅 November 21–23, 2025
🎙️ 50+ speakers | 3 days | fully online
Psychedelic treatments are often framed as breakthroughs—but outcomes vary. This summit places lived experience at the center, inviting patients, trial participants, therapists, and researchers to share real‑world stories of healing, difficulty, and everything in between. Expect streamed interviews, live Q&As, and interactive sessions that move beyond hype and fear toward safety, ethics, inclusion, and realistic expectations.
When we start by listening to the people these treatments are meant to help, clinical science, practice, and policy all get smarter—and care gets safer.
We’re honored to stand alongside fellow supporting partners including OPEN Foundation, California Institute of Integral Studies (CIIS), PsyPAN, Psychedelic Alpha, Psychedelic Association of Canada, TheraPsil, Fireside Project, ACER Integration, and Blossom.
Learn more and register here: https://psychedeliclivedexperiences.com/summit
PSYCH Symposium 2025
On Thursday, 4 December 2025 in London, PSYCH and Drug Science will host the PSYCH Symposium, a one-day gathering designed to promote the potential of psychedelics in addressing today’s mental health crisis.
The event will bring together over 400 delegates and feature leading voices in the field, including Prof. David Nutt, Prof. Sunjeev Kamboj, Dr. David Erritzoe, Prof. Celia Morgan, Dr. Louise Paterson, Dr. Anne Katrin Schlag, Dr. Grace Blest-Hopley, and many more.
PAREA will be represented by Francisca Silva, who will be sharing her expertise in psychedelic research, regulation, and access across Europe, and ensuring that patient needs and lived experience remain central to the conversation.
Learn more and register here: https://www.psychsymposium.com/
ALPS Research Conference
Awareness Research on Psychedelic Science
The ALPS Foundation is delighted to invite you to the fifth edition of the ALPS Awareness Lectures on Psychedelic Science, taking place on Friday and Saturday, October 24–25, 2025, at Campus Biotech in Geneva, Switzerland.
Campus Biotech, a leading center for neuroscience and biotechnology, offers an inspiring setting for two full days of cutting-edge science, meaningful dialogue, and community building. The conference will be held in english.
Participants can earn up to 14 continuing education credits, accredited by FSP and SGPP for psychologists and medical professionals.
Brain Innovation Days
Brain Innovation Days Return to Brussels in October 2025
The 5th edition of the Brain Innovation Days will take place on 15–16 October 2025 at La Tricoterie in Brussels. This two-day event brings together the wider brain health and research community to foster collaboration and accelerate innovation across the brain ecosystem.
This year’s theme, “The Adaptive Brain in a Fast-Evolving World,” will guide discussions across four key subthemes:
Brain Research Frontiers: Driving Europe’s Innovation Leadership
Brain Health Equity: Closing the Gap to Leave No One Behind
Youth Culture: Shaping Brain Health in the Modern World
Beyond Neuroscience: Reimagining the World Through a Brain Health Lens
The event is expected to gather researchers, clinicians, policymakers, and industry leaders from across Europe and beyond.
More details can be found on the official event page.
LAPsyConf: the international conference on the new health ecosystem
For the first time, Buenos Aires will host LaPsyConf: an international conference on mental health, longevity, and emerging therapeutics. We are proud to announce that Tadeusz Hawrot, Founder of PAREA, will deliver the opening address on Day 1 (October 8).
His talk, “Global Issues: Mental Health Indicators, Global Regulation, and Economic Impact,” will set the stage for three days of dialogue among global leaders in science, policy, and innovation. Drawing on his experience working with the World Health Organization and the European Union, Tadeusz will provide a global perspective on how regulation, health data, and economics are shaping the future of mental healthcare.
LaPsyConf will take place October 8–10, 2025, bringing together more than 20 world-renowned experts, including Rick Doblin, Professor David Nutt, Spencer Hawkswell, Chris Timmermann, and Bia Labate, Ph.D.
The program will feature masterclasses, open panels, immersive experiences, a startup demo day, and networking opportunities for clinicians, regulators, investors, researchers, and the general public. The goal is to explore evidence-based, ethical, and sustainable solutions to the global mental health crisis, with a focus on psychedelics, neuroscience, medicinal plants, and longevity science.
As Media Partner, PAREA is proud to support this important initiative. Our community receives a 10% discount on tickets for both the Masterclasses (October 9) and the Open Conference (October 10) with the code PAREA.
Find out more and register here: www.lapsyconf.com
Inawe Foundation for Psymposium Madrid 2025
PAREA is proud to partner with Inawe Foundation, organizer of Psymposium Madrid 2025, which will take place at the Illustrious College of Physicians of Madrid from October 2–4, 2025.
This international conference will bring together experts, researchers, and professionals from diverse disciplines to discuss innovation in mental health, neuroscience, and psychedelics. The program emphasizes combining science, technology, and the humanities to move toward therapeutic models that are more accessible, integrative, and effective.
This year’s program features a strong lineup of international speakers. Among them are Dr. David Erritzøe, Dr. José Carlos Bouso, Dr. Liliana Galindo, Dr. Christopher Timmerman, Dr. Óscar Soto, Marc Aixalá, and others. The majority of interventions will be in Spanish, with simultaneous translation into English available.
As part of this collaboration, the PAREA community will benefit from a 10% discount on tickets with the code PSYMP0S1UM2025.
The 3rd Finnish Interdisciplinary Conference: Psykedeelit 2025: Challenging Psychedelics,
On October 2–4, 2025, Psyty will host the third Finnish Interdisciplinary Conference — Psykedeelit 2025: Challenging Psychedelics. This year’s edition focuses on discussing problems, offering alternative perspectives, and challenging established notions in psychedelic research related to methodology, philosophy, and ethics.
🗓 October 2–4, 2025
📍 Åbo Akademi University, Turku, Finland
🎯 Theme: Challenging Psychedelics — advancing methodological rigor, ethics, decolonizing knowledge, and researcher objectivity across the field.
Keynote speakers include:
• Michiel van Elk (Leiden University) — methodological questions in psychedelic research
• Christine Hauskeller (University of Exeter) — decolonization in psychedelic science
• Daniel Villiger (Uehiro Oxford Institute, University of Oxford) — (bio)ethical issues in psychedelic-assisted therapy
Explore the programme and register here: https://lnkd.in/dz4xUNhK
Psychedelic Therapy: From Evidence to Equity
On October 1st, PAREA will be attending Psychedelic Therapy: From Evidence to Equity, a one-day symposium hosted by the Champalimaud Foundation.
Held just after the PsyPal General Assembly, the event will gather clinicians, researchers, patient representatives, policymakers, and ethicists to explore the development of psychedelic-assisted care in Europe, framed by the four pillars of medical ethics: beneficence, autonomy, non-maleficence, and justice. Speakers include representatives from EU institutions, regulatory agencies, civil society, and leading research groups.
Check out the impressive lineup and register for the symposium here: https://lnkd.in/d5S3u3DG
Borealis Psychedelic Science Summit
We’re pleased to support the upcoming Borealis Psychedelic Science Summit, a two-day scientific conference taking place in Stockholm on September 26–27, as a Community Partner.
The event will bring together researchers, clinicians, policymakers, and students to discuss the latest developments in psychedelic research, mental health, neuroscience, ethics, and healthcare integration.
PAREA’s Tadeusz Hawrot will also be attending the summit.
PAREA community can benefit from a 15% discount using the code PAREA15.
Learn more and register here: https://borealissummit.com
European Parliament event with PsychedeliCare: “Unlocking the potential of Psychedelic-Assisted Therapies for Europe’s Mental Health crisis”
Our first gathering at the European Parliament of the year in partnership with PsychedeliCare, marking the launch of their European Citizen’s Iniative campaign and the re-restablishment of PAREA’s MEP Action Group on Psychedelic in Healthcare. We will discuss the current state of scientific research and emphasise real-world lived experiences with psychedelic therapies, showcasing a call to action for European innovation in this important area.
Pathways To Access Summit
We are delighted to be a co-organiser of the Pathways to Access Summit in The Netherlands in June. Our founder Tadeusz is also speaking at the event. This will be a full day of insightful exploration of the opportunities and challenges around the development, approval and eventual integration of psychedelic medicines ino mainstream European health care.
Launching PsyPal: Pioneering psilocybin-assisted therapy in palliative care
We are pleased to invite you to the launch event of the PsyPal project, funded by the European Union, exploring the use of psilocybin in palliative care. The event will take place at the European Parliament in Brussels, kindly hosted by MEP Cyrus Engerer on 9th April from 12:15 to 13:45. It will be held under the auspices of the MEP Interest Group on Brain Health and Neurological Conditions and the MEP Action Group for the Medical Use of Psychedelics.
Innovating mental Health in the EU Pharma Legislation: Regulatory Pathways for Psychedelic Therapies
On behalf of the MEP Action Group for the Medical Use of Psychedelics, we warmly invite you to an event at the European Parliament, focusing on the potential of psychedelic therapies within the evolving EU pharma legislation context. This event marks the first meeting organized under the umbrella of the recently formed MEP Action Group. The key focus of the meeting will be on discussing the creation of a supportive regulatory environment to stimulate innovation in novel mental health treatments, particularly in the promising field of psychedelic therapies.
REGISTRATION REQUIRED
Launch Of The Parliamentary Action Group
We are thrilled to announce the launch of the Members of the European Parliament Action Group for the Medical Use of Psychedelics (MEP AG), a platform to promote collective action for safe, responsible, and effective psychedelic treatments. The MEP AG, comprised of MEPs from seven EU nations, will be an important vehicle for change. PAREA, along with PsychedelicsEUROPE, provides secretariat support for the Group.
PAREA Event in the European Parliament - Psychedelic-assisted therapies in the treatment of brain disorders
In the last few years, we have witnessed incredible progress in the area of psychedelic science. Now, we need to start moving the discussions about psychedelic-assisted therapies from the scientific conferences to much wider audiences, including policymakers.
On 6th December, we organized our first policy meeting in the European Parliament, looking at the basic ingredients of psychedelic novel treatments captured in the event’s title: “Psychedelic-assisted therapies in the treatment of brain disorders”.
Over 400 people registered for online and in-person attendance, including many EU and government officials. This is a clear sign that Europeans start looking for evidence-based education on psychedelic medicines.
To further shape the discussions on the responsible and safe roll-out of those treatments in the future, at the event, PAREA launched “An appeal to the European Union institutions and Member States”.
Preparing Europe for Novel Psychedelic-Assisted Therapies PAREA launch
We bring together 15 members, including EU patient advocacy groups in the field of mental health, neurology and chronic pain, scientific associations – neuropsychopharmacologists and cancer societies, psychedelic foundations, as well as industry partners. We will be launching this partnership on 23rd June, 2pm – 4pm CEST.